[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585127":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":21,"responsibleParty":37,"collaborators":10,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":10,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"IRCCS Burlo Garofolo","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Anthracycline therapy",null,"Paediatric oncological patients receiving anthracycline chemotherapy",[13],{"name":14,"affiliation":5,"role":15},"Thomas Caiffa, MD","PRINCIPAL_INVESTIGATOR",[17],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+39 0403785248","thomas.caiffa@burlo.trieste.it",[22],{"facility":5,"status":23,"city":24,"state":25,"zip":26,"country":25,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"RECRUITING","Trieste","Italy","34137","IT",{"type":29,"coordinates":30},"Point",[31,32],13.77678,45.64953,{"lat":32,"lon":31},[35],{"name":14,"role":18,"phone":36,"phoneExt":10,"email":20},"+390403785248",{"type":38,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100585127","cardiac-injury-due-to-anthracycline-in-paediatric-oncological-patients-100585127",false,"NCT06898320","Cardiac Injury Due to Anthracycline in Paediatric Oncological Patients","Prediction of Cardiac Injury Due to Anthracycline Chemotherapy in Paediatric Oncological Patients Using Advanced Echocardiography and Circulating Biomarkers.","Inclusion Criteria:\n\n* Paediatric oncological patients 0-18 years\n* Planned start of anthracycline therapy\n* Normal left ventricular systolic function according to International Guidelines before the treatment with AC\n\nExclusion Criteria:\n\n* Previous anthracycline treatment, bone marrow transplantation or chest radiation\n* Pre-anthracycline treatment echocardiographic evidence of:\n* More than mild pericardial effusion\n* More than mild mitral regurgitation\n* Poor echocardiographic acoustic window","ALL","0 Years","18 Years",{"count":50,"type":51},22,"ESTIMATED","OBSERVATIONAL","The study investigates the role of echocardiography and of serum biomarkers (NT-proBNP, cardiac Troponin-I) in predicting cardiac injury in a cohort of paediatric oncological patients treated with Anthracycline chemotherapy.",[55,56],"Heart Injuries","Anthracycline",[58,59,60,61],"Cardiac injury","Anthracycline chemotherapy","echocardiography","Circulating biomarkers","2025-05-06",{"date":64,"type":65},"2025-05-09","ACTUAL",{"date":67,"type":65},"2023-07-21",{"date":69,"type":51},"2033-07-21",{"name":5,"class":6},1]